AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02829411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workforce Readiness Program
Description: job readiness workshops, organized into ten daily sessions over two weeks.
Study NCT02829411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship education
Description: 25-hours of Within My Reach curriculum and relationship skills education sessions
Study NCT02623790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (butter)
Description: Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
Study NCT02623790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (cheddar cheese)
Description: Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
Study NCT02623790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (cream cheese)
Description: Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
Study NCT02807142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NC 1 cell therapy
Description: All patients will be treated with NC1
Study NCT04759495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)
Description: rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
Study NCT04759495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)
Description: FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
Study NCT03758833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preimplantation genetic test of embryo by new generation sequencing (NGS)
Description: This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
Study NCT03758833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single embryo transfer
Description: Transfer of single embryo
Study NCT03758833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single embryo transfer
Description: Transfer of single embryo
Study NCT00762502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: soft contact lens
Study NCT00762502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A toric contact lens
Description: soft contact lens
Study NCT03758833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double embryo tranfer
Description: Transfer of two embryos
Study NCT02504502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: enhanced genomic report
Description: a patient-centered version of a genomic results report delivered to patient through the electronic record portal
Study NCT02504502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced genomic report
Description: a patient-centered version of a genomic results report delivered to patient through the electronic record portal
Study NCT02897219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: Oral administration once daily
Study NCT02897219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once daily
Study NCT02897219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Therapy
Description: Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
Study NCT02897219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Therapy
Description: Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
Study NCT03376646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort A: Dissolve™
Description: Dissolve™ are to be used in the trial
Study NCT03376646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cohort A: Resolute™ Integrity
Description: Resolute™ Integrity are to be used in the trial
Study NCT03376646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort B: Dissolve™-2.00mm
Description: Dissolve™ are to be used in the trial
Study NCT01856478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: intravenous bolus injection, once weekly
Study NCT01856478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: oral intake, once daily
Study NCT02118727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Study NCT02118727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Memantine)
Description: All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Study NCT02693002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol/Norethindrone acetate
Description: Estradiol/Norethindrone acetate 1mg/0.5 mg
Study NCT02693002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive ingredient
Study NCT02699931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric3D
Description: Oral-B 3D with orthodontic head
Study NCT02699931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual
Description: Oral-B orthodontic
Study NCT02453035 — intervention group
Intervention type: DEVICE
Intervention: PTCA - Desolve Scaffold
Description: Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
Study NCT04800887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TECNIS Eyhance intraocular lens
Description: Cataract surgery and implantation with extended depth of focus intraocular lens
Study NCT04800887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal intraocular lens Tecnis ZCB00
Description: Cataract surgery and implantation with monofocal intraocular lens
Study NCT00986921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 200 mg
Description: mifepristone would be given the day before the procedure
Study NCT03511911 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaginal palpation
Description: vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
Study NCT01613638 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: meconium samples + maternal self-questionnaire
Description: meconium samples + maternal self-questionnaire
Study NCT00986921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: osmotic dilator insertion
Description: osmotic dilators (3-6) would be inserted as usual the day before the procedure
Study NCT00863252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Orally at 0.75 g bd to 1 g bd for 6 months
Study NCT00863252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: angiotensin blockade
Description: Continuation of angiotensin blockade
Study NCT01559948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic stabilization exercise
Description: The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
Study NCT01559948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stabilization exercise
Description: The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
Study NCT01559948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint belt
Description: The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
Study NCT03661931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DQPN Validation
Description: We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
Study NCT00090493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3
Description: vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
Study NCT03758833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double embryo tranfer
Description: Transfer of two embryos
Study NCT01493765 — intervention group
Intervention type: OTHER
Intervention: Simulator training with expert scoring
Description: Residents will be trained using surgical simulation
Study NCT04692402 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Solitaire™ thrombus retrieval device
Description: After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
Study NCT01016509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of \<180 mg/dl.
Study NCT01016509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of \<200 mg/dl.
Study NCT00406978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
Study NCT00406978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
Study NCT00090493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
Description: Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
Study NCT04424706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed as type 2 diabetes without atherosclerosis
Description: patients diagnosed as type 2 diabetes without atherosclerosis
Study NCT04424706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed as type 2 diabetes with atherosclerosis
Description: patients diagnosed as type 2 diabetes with atherosclerosis
Study NCT04424706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: people without type 2 diabetes or atherosclerosis
Description: normal people without type 2 diabetes or atherosclerosis
Study NCT02258373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGM+BGM
Description: Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
Study NCT02258373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Only
Description: Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
Study NCT02425878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Study NCT02425878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01832558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study NCT01832558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02819752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT02819752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy - Standard Treatment
Study NCT02819752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy - Standard Treatment
Study NCT01023945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01023945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT00406978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
Study NCT00406978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
Study NCT03650933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CHOP
Description: 6 cycles(each cycle is 3 weeks)
Study NCT04613908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuro muscular electro stimulation
Description: We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
Study NCT04613908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization protocol
Description: The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~* Level 1: MRC (shoulder) \<3 + MRC \<3 (hip).~* Level 2: MRC (shoulder) ≥ 3 + MRC (hip) \<3.~* Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~* Level 4: Standing without assistance and walking with or without assistance.
Study NCT04613908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care or usual rehabilitation
Description: routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
Study NCT03396029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually tailored lifestyle feedback
Description: The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
Study NCT03396029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard leaflet
Description: The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
Study NCT01649232 — intervention group
Intervention type: DEVICE
Intervention: Active tDCS
Description: tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).